<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00112502</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0662</org_study_id>
    <secondary_id>MDA-ID-02586</secondary_id>
    <secondary_id>NCI-6636</secondary_id>
    <secondary_id>MDA-2004-0662</secondary_id>
    <secondary_id>CDR0000432954</secondary_id>
    <secondary_id>NCI-2009-00076</secondary_id>
    <nct_id>NCT00112502</nct_id>
  </id_info>
  <brief_title>Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme</brief_title>
  <official_title>A Randomized, Factorial-Design, Phase II Trial of Temozolomide Alone and in Combination With Possible Permutations of Thalidomide, Isotretinoin and/or Celecoxib as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.
      Thalidomide may stop the growth of glioblastoma multiforme by blocking blood flow to the
      tumor. Isotretinoin may help cells that are involved in the body's immune response to work
      better. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed
      for cell growth. It is not yet known which temozolomide-containing regimen is more effective
      in treating glioblastoma multiforme.

      PURPOSE: This randomized phase II trial is studying eight different temozolomide-containing
      regimens to compare how well they work in treating patients who have undergone radiation
      therapy for glioblastoma multiforme.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the efficacy of adjuvant temozolomide (TMZ) alone or in combination with
           thalidomide and/or isotretinoin and/or celecoxib, in terms of 6-month progression-free
           survival, in patients who have undergone radiotherapy for supratentorial glioblastoma
           multiforme.

        -  Compare the toxicity of these regimens in these patients.

      OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 8 treatment
      arms.

        -  Arm I: Patients receive oral temozolomide once daily on days 1-7 and 15-21.

        -  Arm II: Patients receive temozolomide as in arm I and oral thalidomide once daily on
           days 1-28.

        -  Arm III: Patients receive temozolomide as in arm I and oral isotretinoin twice daily on
           days 1-21.

        -  Arm IV: Patients receive temozolomide as in arm I and oral celecoxib twice daily on days
           1-28.

        -  Arm V: Patients receive temozolomide as in arm I, thalidomide as in arm II, and
           isotretinoin as in arm III.

        -  Arm VI: Patients receive temozolomide as in arm I, thalidomide as in arm II, and
           celecoxib as in arm IV.

        -  Arm VII: Patients receive temozolomide as in arm I, isotretinoin as in arm III, and
           celecoxib as in arm IV.

        -  Arm VIII: Patients receive temozolomide as in arm I, thalidomide as in arm II,
           isotretinoin as in arm III, and celecoxib as in arm IV.

      In all arms, treatment repeats every 28 days for up to 12 courses in the absence of disease
      progression or unacceptable toxicity. Patient may receive additional courses of therapy at
      the discretion of the treating physician.

      After completion of study treatment, patients are followed for at least 30 days and then
      every 3 months thereafter.

      PROJECTED ACCRUAL: A total of 180 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with no disease progression, measured at 6 months. A combination of the neurological examination and MRI brain scan used to define progression.</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">178</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Arm I: TMZ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Temozolomide (TMZ) 150 mg/m^2 once daily on days 1-7 and 15-21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II: TMZ + Thalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide as in arm I and oral Thalidomide (Thal) once daily on days 1-28 (starting dose 200 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III: TMZ + Isotretinoin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide as in Arm I and oral Isotretinoin 40 mg/m^2 twice daily on days 1-21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV: TMZ + Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide as in arm I and oral Celecoxib 400 mg twice daily on days 1-28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm V: TMZ + Thalidomide + Isotretinoin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide as in arm I, Thalidomide as in arm II, and Isotretinoin as in arm III.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm VI: TMZ + Thalidomide + Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide as in Arm I, Thalidomide as in Arm II, and Celecoxib as in Arm IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm VII: TMZ + Isotretinoin + Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide as in Arm I, Isotretinoin as in Arm III, and Celecoxib as in Arm IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide as in Arm I, Thalidomide as in Arm II, Isotretinoin as in Arm III, and Celecoxib as in Arm IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>400 mg orally twice a day continuous dosing</description>
    <arm_group_label>Arm IV: TMZ + Celecoxib</arm_group_label>
    <arm_group_label>Arm VI: TMZ + Thalidomide + Celecoxib</arm_group_label>
    <arm_group_label>Arm VII: TMZ + Isotretinoin + Celecoxib</arm_group_label>
    <arm_group_label>Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin</intervention_name>
    <description>40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
    <arm_group_label>Arm III: TMZ + Isotretinoin</arm_group_label>
    <arm_group_label>Arm V: TMZ + Thalidomide + Isotretinoin</arm_group_label>
    <arm_group_label>Arm VII: TMZ + Isotretinoin + Celecoxib</arm_group_label>
    <arm_group_label>Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib</arm_group_label>
    <other_name>Accutane</other_name>
    <other_name>13-Cis-Retinoic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>150 mg/m2 orally daily, 7 days on treatment, 7 days off.</description>
    <arm_group_label>Arm I: TMZ</arm_group_label>
    <arm_group_label>Arm II: TMZ + Thalidomide</arm_group_label>
    <arm_group_label>Arm III: TMZ + Isotretinoin</arm_group_label>
    <arm_group_label>Arm IV: TMZ + Celecoxib</arm_group_label>
    <arm_group_label>Arm V: TMZ + Thalidomide + Isotretinoin</arm_group_label>
    <arm_group_label>Arm VI: TMZ + Thalidomide + Celecoxib</arm_group_label>
    <arm_group_label>Arm VII: TMZ + Isotretinoin + Celecoxib</arm_group_label>
    <arm_group_label>Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib</arm_group_label>
    <other_name>Temodar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved)</description>
    <arm_group_label>Arm II: TMZ + Thalidomide</arm_group_label>
    <arm_group_label>Arm V: TMZ + Thalidomide + Isotretinoin</arm_group_label>
    <arm_group_label>Arm VI: TMZ + Thalidomide + Celecoxib</arm_group_label>
    <arm_group_label>Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib</arm_group_label>
    <other_name>Thalomid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed supratentorial glioblastoma multiforme

          -  Must have undergone a biopsy OR subtotal or gross total resection of the tumor

          -  Must have completed post-operative (or post-biopsy) radiotherapy within the past 5
             weeks

               -  No progressive disease after radiotherapy

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Karnofsky 60-100%

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

        Hepatic

          -  Serum glutamate pyruvate transaminase (SGPT) &lt; 2 times upper limit of normal (ULN)

          -  Alkaline phosphatase &lt; 2 times ULN

          -  Bilirubin ≤ 1.5 mg/dL

        Renal

          -  blood urea nitrogen (BUN) ≤ 1.5 times ULN

          -  Creatinine ≤ 1.5 times ULN

        Immunologic

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biological composition to celecoxib or to sulfonamides

          -  No asthma, urticaria, or allergic reactions to aspirin or other NSAIDs

          -  No active infection

        Gastrointestinal

          -  No inflammatory bowel disease

          -  No history of peptic ulcer disease

          -  No gastrointestinal bleeding within past 3 months

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective double-method contraception during and for 2
             months after study participation

               -  Fertile female patients randomized to receive thalidomide must use effective
                  double-method contraception for ≥ 4 weeks before, during, and ≥ 4 weeks after
                  completion of study therapy

               -  Fertile male patients randomized to receive thalidomide must use effective
                  contraception during and for ≥ 4 weeks after completion of study therapy

          -  No blood donation (for patients randomized to receive thalidomide)

          -  No history of any other cancer except nonmelanoma skin cancer or carcinoma in situ of
             the cervix or cancer that is in complete remission and patient completed all therapy
             for that disease ≥ 3 years ago

          -  No other disease that would obscure toxicity or dangerously alter drug metabolism
             (e.g., severe connective tissue disease)

          -  No other serious medical illness

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Prior temozolomide in combination with radiotherapy allowed

          -  No other prior or concurrent chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  See Disease Characteristics

          -  See Chemotherapy

        Surgery

          -  See Disease Characteristics

          -  No concurrent surgery

        Other

          -  No other concurrent non-steroidal anti-inflammatory drugs (NSAIDs) (for patients
             randomized to receive celecoxib)

          -  No other concurrent investigational drugs

          -  No other concurrent anticancer therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Penas-Prado, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hembree Mercy Cancer Center at St. Edward Mercy Medical Center</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center at Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806-2134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Atlanta Regional</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342-1701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Central Illinois</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214-3882</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Grand Rapids</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Kalamazoo</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007-3731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research for the Ozarks</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Upstate Carolina</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas (UT) MD Anderson Cancer Center Official Website</description>
  </link>
  <results_reference>
    <citation>Gilbert MR, Gonzalez J, Hunter K, Hess K, Giglio P, Chang E, Puduvalli V, Groves MD, Colman H, Conrad C, Levin V, Woo S, Mahajan A, de Groot J, Yung WK. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro Oncol. 2010 Nov;12(11):1167-72. doi: 10.1093/neuonc/noq100. Epub 2010 Aug 20.</citation>
    <PMID>20729242</PMID>
  </results_reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2005</study_first_submitted>
  <study_first_submitted_qc>June 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2005</study_first_posted>
  <last_update_submitted>September 23, 2014</last_update_submitted>
  <last_update_submitted_qc>September 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

